<DOC>
	<DOCNO>NCT01833884</DOCNO>
	<brief_summary>More 90 % patient Hodgkin lymphoma ( HL ) recover thanks conventional polychemotherapy regimens - ABVD BEACOPP - without radiotherapy . Nevertheless , patient relapse others resistant treatment . These patient represent 2-5 % stage I / II 5-10 % disseminated stage . The usual prognostic index base clinical biological data ( supradiaphragmatic HL : EORTC advance HL International Prognostic Score ) always detect patient risk . New prognostic factor require screen high risk patient . Among available biological factor , retain cytokine secrete tumor cell cell environment . Indeed , prognostic value plasma cytokine level soluble receptor recently describe least two team . Olivier CASASNOVAS set prognostic index base quantity IL-1 RA , IL-6 , sCD30 TNFR1 diagnosis , V. Diehl team publish prognostic value decrease TARC ( CC Thymus Activation-related chemokine ) . In daily practice , early assessment response PET CT-scan undeniable prognostic factor . Early identification no-response relapse , fact , base clinical imaging ( PET-CT scan ) . We propose evaluate decrease cytokine concentration prognostic value ( TARC , IL-6 , IL1-RA , sCD30 , TNFR1 ) marker response treatment early follow-up . The dosage cytokine pair radiological assessment . A correlation decrease cytokine plasma level overtime event-free survival search afterwards .</brief_summary>
	<brief_title>Kinetic Cytokines Decrease Hodgkin Lymphoma Prognostic</brief_title>
	<detailed_description>To evaluate decrease cytokine concentration prognostic value marker response , dosage TARC , IL-6 , IL1-RA , sCD30 TNFR1 perform treatment : diagnosis , cycle 1 day 15 , cycle 2 Day 1 , cycle 3 Day 1 , Day 1 consolidation ( Cycle 5 day 1 radiotherapy ) evaluation end treatment . early follow-up dosage cytokine perform 3 month end treatment . An evaluation Event Free Survival do 3 year diagnosis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Hodgkin Lymphoma diagnosis III IIIIV Stages untreated Patient ( include corticosteroid ) Patient treat follow exclusively center Henri Becquerel Informed Consent sign psychological , social family condition allow suitable followup study Mental deficiency allow good understanding study procedure positive HIV serology positive B C Hepatitis serology Pregnant lactating Patient register social security scheme equivalent situation Patient period exclusion another biomedical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hodgkin Lymphoma , Adult</keyword>
	<keyword>Cytokines</keyword>
	<keyword>TARC</keyword>
	<keyword>IL-6</keyword>
	<keyword>IL1-RA</keyword>
	<keyword>sCD30</keyword>
	<keyword>TNFR1</keyword>
</DOC>